News
TGTX
29.74
+7.48%
2.07
TG Therapeutics Reports Strong Revenue and Future Goals
TipRanks · 14h ago
TG THERAPEUTICS INC - SEES FY 2025 GLOBAL REVENUE $540 MILLION
Reuters · 14h ago
TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug
Dow Jones · 15h ago
B.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)
TipRanks · 20h ago
What's Going On With TG Therapeutics Stock Tuesday?
Benzinga · 21h ago
BUZZ-U.S. STOCKS ON THE MOVE-B Riley, H&E Equipment, Emergent BioSolutions
Reuters · 21h ago
TG Therapeutics says 2024 Briumvi sales topped expectations
Seeking Alpha · 22h ago
BUZZ-TG Therapeutics rises after preliminary Q4 net product revenue tops estimates
Reuters · 23h ago
TG Therapeutics Expects Q4 BRIUMVI US Net Product Revenue Of $103.6M, FY24 RIUMVI US Net Product Revenue Of $310M, FY25 Total Revenue Of $540M
Benzinga · 23h ago
TG Therapeutics sees Q4 BRIUMVI U.S. net product revenue $103.6M
TipRanks · 23h ago
TG Therapeutics targets FY25 global revenue $540M, consensus $537.84M
TipRanks · 23h ago
*TG Therapeutics Sees 2025 U.S. Net Pdt Rev of About $525M >TGTX
Dow Jones · 23h ago
*TG Therapeutics Sees 2025 Operating Expense of About $300M >TGTX
Dow Jones · 23h ago
*TG Therapeutics Sees 2025 Rev $540M >TGTX
Dow Jones · 23h ago
TG THERAPEUTICS INC QTRLY BRIUMVI U.S. NET PRODUCT REV EXPECTED TO BE $103.6 MLN
Reuters · 23h ago
TG THERAPEUTICS INC OUTLOOK FY 2025 TARGET TOTAL GLOBAL REVENUE OF ABOUT $540 MILLION
Reuters · 23h ago
TG THERAPEUTICS INC <TGTX.O> FY2025 REV VIEW $549.5 MLN -- LSEG IBES DATA
Reuters · 23h ago
Bank of America Securities Reaffirms Their Sell Rating on TG Therapeutics (TGTX)
TipRanks · 1d ago
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst
Seeking Alpha · 1d ago
Weekly Report: what happened at TGTX last week (0106-0110)?
Weekly Report · 2d ago
More
Webull provides a variety of real-time TGTX stock news. You can receive the latest news about Tg Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.